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Abstract
Background: Although highly effective prevention interventions exist, the epidemic of paediatric HIV continues to
challenge control efforts in resource-limited settings. We reviewed the cost-effectiveness of interventions to
prevent mother-to-child transmission (MTCT) of HIV in low- and middle-income countries (LMICs). This article
presents syntheses of evidence on the costs, effects and cost-effectiveness of HIV MTCT strategies for LMICs from
the published literature and evaluates their implications for policy and future research.
Methods: Candidate studies were identified through a comprehensive database search including PubMed, Embase,
Cochrane Library, and EconLit restricted by language (English or French), date (January 1st, 1994 to January 17
th,
2011) and article type (original research). Articles reporting full economic evaluations of interventions to prevent or
reduce HIV MTCT were eligible for inclusion. We searched article bibliographies to identify additional studies. Two
authors independently assessed eligibility and extracted data from studies retained for review. Study quality was
appraised using a modified BMJ checklist for economic evaluations. Data were synthesised in narrative form.
Results: We identified 19 articles published in 9 journals from 1996 to 2010, 16 concerning sub-Saharan Africa.
Collectively, the articles suggest that interventions to prevent paediatric infections are cost-effective in a variety of
LMIC settings as measured against accepted international benchmarks. In concentrated epidemics where HIV
prevalence in the general population is very low, MTCT strategies based on universal testing of pregnant women
may not compare well against cost-effectiveness benchmarks, or may satisfy formal criteria for cost-effectiveness
but offer a low relative value as compared to competing interventions to improve population health.
Conclusions and Recommendations: Interventions to prevent HIV MTCT are compelling on economic grounds in
many resource-limited settings and should remain at the forefront of global HIV prevention efforts. Future cost-
effectiveness analyses can help to ensure that pMTCT interventions for LMICs reach their full potential by focussing
on unanswered questions in four areas: local assessment of rapidly evolving HIV MTCT options; strategies to
improve coverage and reach underserved populations; evaluation of a more comprehensive set of MTCT
approaches including primary HIV prevention and reproductive counselling; integration of HIV MTCT and other
sexual and reproductive health services.
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Due to the availability of highly effective interventions to
prevent mother-to-child transmission (MTCT), the birth
of children with HIV is now rare in high-income coun-
tries. However, on a global scale, the epidemic of pae-
diatric HIV continues to challenge disease control
efforts. Worldwide, UNAIDS estimates that the number
of children younger than 15 years of age living with
HIV/AIDS increased from 1.6 million [95% CI: 1.4 mil-
lion to 2.1 million] in 2001 to 2.5 million [95% CI: 1.7
million to 3.4 million] in 2009 [1,2]. An estimated
370 000 [95% CI: 230 000 to 510 000] children were
newly infected in 2009 [2].
Virtually all HIV-infected children acquire the infec-
tion through MTCT, which can occur during pregnancy,
labour and delivery, or through breastfeeding. In the
absence of any intervention an estimated 15-30% of
mothers with HIV infection will transmit the infection
during pregnancy and delivery, and breastfeeding by an
infected mother increases the risk by a further 5-20% to
a total of 20-45% [3-5]. Without treatment, most HIV-
infected children experience severe morbidity and early
death.
The risk of MTCT has been reduced to below 2% in
high-income countries by universal HIV screening of
pregnant women and a suite of interventions for those
identified as HIV+ that includes: (1) antiretroviral (ARV)
prophylaxis in combinations of three or more drugs
given to women during pregnancy and labour, and ARV
prophylaxis given to the infant in the first weeks of life;
(2) obstetrical interventions including elective caesarean
delivery (prior to onset of labour and membrane rupture);
and (3) complete avoidance of breastfeeding. Although
evidence suggests that the three-pronged approach
described above is clinically most efficacious, a variety of
less complex strategies to prevent HIV MTCT (pMTCT)
have been proposed for developing countries each with
different resource requirements and levels of associated
clinical benefit [6-11].
The World Health Organization (WHO) promotes a
comprehensive approach to prevent MTCT based on
four components: (1) primary prevention of HIV infec-
tion among women of childbearing age; (2) preventing
unintended pregnancies among women living with HIV;
(3) preventing HIV transmission from a woman living
with HIV to her infant; and (4) providing appropriate
treatment, care and support to mothers living with HIV
and their children and families [12]. Recognising the
multifaceted tradeoffs involved in selecting among alter-
native pMTCT approaches and their sensitivity to local
context, current WHO technical guidelines leave consid-
erable flexibility to decision makers at the country level
[13,14]. In developing countries where virtually all HIV
MTCT now occurs, constraints related to health system
infrastructure, availability of trained personnel, and
availability of resources are an inescapable part of deci-
sion-making. Information on the economic value of
alternative pMTCT strategies can contribute to the
design of evidence-based policy.
As access to services for preventing MTCT has
increased worldwide, the number of children newly
infected with HIV has dropped sharply. Incident cases
for 2009 are down by almost one quarter as compared to
five years earlier [2]- an unprecedented achievement that
brings renewed hope to the global community. To build
upon these successes, policies and programmes must
reflect bold and intelligent choices. Our objective was to
conduct a systematic review of the cost-effectiveness of
interventions to prevent mother-to-child transmission
(MTCT) of HIV in low- and middle-income countries
(LMICs). This article presents syntheses of evidence on
the costs, effects and cost-effectiveness of pMTCT strate-
gies for LMICs from the published literature and evalu-
ates their implications for policy and future research.
Methods
Data sources
To identify all published economic evaluations of interven-
tions to prevent MTCT of HIV we searched the PubMed,
Medline, Embase, Web of Science, Google Scholar,
Cochrane Library, Econ Lit, National Health Service Eco-
nomic Evaluation Database (NHS EES) and Latin Ameri-
can and Caribbean Health Sciences Literature (LILACS)
databases from January 1
st, 1994 (date of the earliest phar-
maceutical HIV MTCT interventions
1,2)t oJ a n u a r y1 7
th,
2011. An information retrieval specialist helped to develop
the PubMed search string: “Cost-Benefit Analysis"[Mesh]
OR “Costs and Cost Analysis"[Mesh] OR “Program Eva-
luation"[Mesh] OR “Cost Effectiveness"[Title] OR “Cost
utility"[Title] OR “Health Care Economics and Organiza-
tions"[Mesh]) AND “HIV Seropositivity"[Mesh] OR
“HIV"[title] OR “HIV"[Mesh] OR “Acquired Immunodefi-
ciency Syndrome"[Mesh] AND “Disease Transmission,
Vertical"[Mesh] OR “pmtct"[Mesh] OR “PMTCT"[Title].
Our search was restricted to articles in English and
French. We supplemented the database search by check-
ing article bibliographies for relevant studies and contact-
ing experts to enquire about ongoing research. All
candidate studies were exported to Endnote bibliographic
software [15].
Study selection
Inclusion and exclusion criteria were designed to retain
all and only those studies pertaining to components 1-3
of the WHO MTCT strategy, which focus on prevention
[12]. Two researchers independently reviewed the titles
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criteria:
(i) Studies - All original research articles published
in peer-reviewed scientific journals offering full eco-
nomic evaluations of strategies to prevent MTCT of
HIV in pregnant women in LMICs (as defined by
the World Bank) [16] were candidates for inclusion.
Cost-effectiveness, cost-benefit and cost-utility
designs as defined by Drummond and colleagues
[17] were all acceptable.
(ii) Participants - Women at risk of transmitting
HIV infection to their children. This could include
pregnant women or those at risk of pregnancy,
regardless of HIV status.
(iii) Interventions - All interventions to prevent or
reduce HIV MTCT, including (but not limited to)
strategies for antiretroviral therapy and replacement
feeding.
We excluded articles with the following characteristics:
(i) Studies focusing on high-income countries as
defined by the World Bank [16]
(ii) Studies that are not original, peer-reviewed
research articles (reviews, monographs and confer-
ence abstracts)
(iii) Studies of MTCT that provide only cost analyses
(incomplete economic evaluations)
(iv) Studies focusing on general HIV/AIDS preven-
tion without reference to MTCT
(v) Studies assessing the cost-effectiveness of thera-
pies for children already infected with HIV
Review was not blinded. On the basis of initial title and
abstract screening, candidate articles were retained for
full text review. Articles that met the inclusion criteria
were retained for data extraction. Authors jointly deter-
mined study inclusion on the basis of their individual
assessments and discussion. At each stage, differences of
opinion were resolved through building consensus and,
in rare instances, appeal to a third reviewer [Figure 1].
Data extraction and synthesis
Each author extracted relevant information indepen-
dently using a standardised data extraction form, pre-
tested on a subset of the sample. Data extraction was
not blinded. Discrepancies were harmonised through
building consensus. We contacted study authors with
unresolved queries. Fields extracted are summarised in
Tables 1, 2, 3 and 4. Due to the diversity of methodolo-
gical approaches, interventions, study populations and
programme comparators, we took a narrative approach
to data synthesis, as is standard for systematic reviews
of cost-effectiveness studies. Principal summary mea-
sures for the study are summarised in Table 4 and
include cost per infant HIV infection averted, cost per
life year gained, and cost per QALY or DALY.
Assessment of study quality
We adapted the British Medical Journal’s quality assess-
ment checklist for the conduct and reporting of eco-
nomic evaluations [18], a 35-item scale that has recently
been used in systematic reviews of cost-effectiveness
studies [19,20]. To assess risk of bias, we included an
additional item to reflect whether the article included
information on sponsorship or conflict of interest. For
each article, the resulting 36 items were scored as pre-
sent/satisfactory, absent/unsatisfactory, or not applicable.
We summed the number of absent/unsatisfactory
responses to obtain a global score in which higher
values represent poorer quality [21]. Quality was
assessed independently by two reviewers and disagree-
ments resolved through discussion. Quality assessment
did not affect data synthesis, but did influence interpre-
tation of results. The review protocol is available from
the corresponding author.
Results
Study overview
We identified 19 articles published in 9 journals from
1996 to 2010, with the majority (16 of 19) focussing on
s u b - S a h a r a nA f r i c a [ T a b l e1 ] .T e ns t u d i e sp e r f o r m e d
only cost-effectiveness analyses (CEA), two performed
only cost-utility analyses (CUA), while seven performed
both CEA and CUA. No cost-benefit studies were
found. All articles modelled hypothetical cohorts. Stu-
dies were conducted in a variety of epidemic contexts
with HIV prevalence in pregnant women ranging from
under 1% to 26%. Two studies modelled pMTCT
options for ‘low’ or ‘concentrated’ epidemics, in which
HIV is confined mainly to sub-populations with specific
risk profiles and HIV prevalence in the general popula-
tion (and, thus, pregnant women) is under 1% [22,23].
Most addressed generalised epidemics where more than
1% of the general population is HIV positive. Country
income levels ranged from low to upper middle [16].
Drug regimens and related efficacy estimates were
drawn from clinical trials, as was information on the
natural history of MTCT [Additional file 1].
Components 1 to 3 of the WHO pMTCT strategy deal
with HIV prevention [12] and related articles were
included in this review. Intervention options were
unequally distributed among components. Two studies
considered the value of primary prevention of HIV infec-
tion among women of childbearing age (component 1)
[24,25], and two articles considered prevention of unin-
tended pregnancies among women living with HIV
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ing HIV transmission from a woman living with HIV to
her infant (component 3). Of these, three examined dif-
ferent approaches to voluntary counselling and testing
(VCT) [27-29]; fifteen explored alternative strategies
based on antenatal, intrapartum or postpartum options
using drug regimens, and three evaluated different
approaches to infant feeding for prevention of postpar-
tum transmission in the context of ART-based pMTCT
[30-32]. Component 4 of the WHO strategy focuses on
treatment and care rather than on prevention and related
papers were excluded [22-40].
Costs
All 19 articles considered costs incurred under the per-
spective of the public payer of healthcare costs[Table 2].
One study [33] also evaluated costs from a societal per-
spective. Costs evolved considerably during the 14-year
period (1996 - 2010) over which articles were published
due to a sharp drop in drug prices, shorter duration
of pMTCT interventions, and increased adherence to
treatment [41].
Intervention costs
There was considerable agreement on the components of
intervention costs. All 19 studies included the costs of
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Figure 1 Flow diagram of study selection.
Johri and Ako-Arrey Cost Effectiveness and Resource Allocation 2011, 9:3
http://www.resource-allocation.com/content/9/1/3
Page 4 of 16Table 1 Overview of economic evaluations of interventions to reduce mother to child transmission (MTCT) of HIV
Study Location
(Income)
1
Adult HIV
Prevalence
2
Study Population
3 Interventions
4 Study
design
5
[32] SSA
6 1% - 26% 100 000 pregnant women (0) No intervention
(1) CDC Thai
CEA
[33] SSA 1% - 26% 100 pregnant women (0) No intervention
(1) PETRA-A
(2) PETRA-B
(3) PETRA-C
CEA & CUA
[29] South Africa (UM) 18.10% 8421 pregnant women
representing a high
prevalence health district
(26% HIV+)
(0) No intervention
(1) ACTG 076 with breastfeeding, current infrastructure
(2) ACTG 076 without breastfeeding, enhanced
infrastructure
(3) PETRA-A, enhanced infrastructure
CEA
[34] SSA 1% - 26% 20 000 pregnant women (0) No intervention
(1) HIVNET 012 (targeted)
(2) HIVNET 012 (universal)
(3) PETRA-A
(4) PETRA-B
(5) CDC Thai (targeted)
CEA & CUA
[30] South Africa (UM) 18.10% 20 000 pregnant women (0) No intervention
(1) Formula feeding (FF) recommended from birth
(2) FF recommended from 4 months
(3) FF recommended from 7 months
(4) FF supplied from birth
(5) ACTG 076
(6) PETRA-B
(7) CDC Thai
8) CDC Thai + FF recommended
(9) CDC Thai + FF supplied
CEA
[35] SSA 1% - 26% 10 000 pregnant women (0) No intervention
(1) Antenatal HIVNET 012 (targeted)
(2) Antenatal HIVNET 012 (universal)
(3) Labour and delivery universal maternal NVP
(4) Labour and delivery universal infant therapy
CEA
[36] South Africa (UM) 18.10% 1 340 797 pregnant women
(annual national average)
(0) No intervention
(1) CDC Thai (targeted) + FF supplied, enhanced
infrastructure
CEA
[37] South Africa (UM) 18.10% 920 000 HIV+ pregnancies
nationally over 5 years
(0) No intervention
(1) 25% HIV+ pregnant women and infants receive ART
7
(2) Strategy (1) at 75%
(3) 100% pregnant women (HIV+ and HIV-) receive ART
(4) 3-drug ART of 25% of non-pregnant HIV+ adults
CEA
[23] Mexico (UM) 0.30% 958 294 pregnant women
(national birth cohort)
(0) 4% VCT
8 to pregnant women + ACTG 076 or HIVNET
012
(1) Strategy (1) at 85% VCT
(2) 30% VCT to pregnant women at highest risk + ACTG
076 or HIVNET 012
(3) VCT to HIV+ pregnant women + ACTG 076 or HIVNET
012
(4) Strategy (4) plus VCT to 15% of late presenters
CEA
[25] SSA 1% - 26% Simulation of national MTCT
programs using data from 8
SSA countries
(0) No intervention
(1) HIVNET 012
CEA & CUA
[31] Zambia (L) 15.20% 40 000 pregnant women Usual care (UC) = VCT + HIVNET 012
(0) UC + BF for 6 months
(1) UC + BF for 12 months
(2) UC + FF for 12 months
(3) UC + BF for 6 months + daily infant NVP
(4) VCT + Maternal 3-drug ART in pregnancy + 3-drug ART
for 6 months BF
(5) Same as (4), but only for women with CD4 < = 200
CUA
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Page 5 of 16staff time to deliver the interventions, drugs and HIV
testing, as well as additional costs specific to the interven-
tions under study. Reported unit costs varied across stu-
dies, reflecting differences among countries in which
costs were recorded, the cost year and the price of the
intervention at that point in time. VCT costs ranged
from $4 to $18.5 per episode; formula feeding costs were
estimated at $15-$30 per month [23,30,31].
Costs generated or offset
Thirteen studies considered the lifetime medical costs of
HIV+ children (total or net). Estimates ranged from
$141 to over $11,000. One study included the lifetime
cost of HIV treatment for adults [23]. One article con-
sidered costs associated with an adverse event, NVP
resistance in mothers [28].
Health System Strengthening (HSS)
Particularly in resource-limited settings, it may be unrea-
listic to model the cost-effectiveness of wide scale provi-
sion of an intervention based on incremental patient costs
(intervention costs at the point of delivery) at a single site
with relatively developed infrastructure. We use the term
“health system strengthening” to capture a variety of
Table 1 Overview of economic evaluations of interventions to reduce mother to child transmission (MTCT) of HIV
(Continued)
[27] Thailand (LM) 1.40% 100 000 pregnant women (0) 1 VCT + Maternal and infant ZDV as ACTG 076
(1) 1 VCT + maternal and infant NVP as HIVNET 012
(2) (1) for antenatal care + (2) for late arrivals
(3) 1 VCT + combined ACTG 076 + HIVNET 012
(4) (0) with 2 VCT
(5) (1) with 2 VCT
(6) (2) with 2 VCT
(7) (3) with 2 VCT
CEA
[22] India (LM) 0.50% 100 000 sexually active
women aged 15-49
(0) No intervention
(1) Universal screening in all states + HIVNET 012
(2) Universal screening in 6 highest prevalence states +
HIVNET 012
CEA & CUA
[24] SSA 1% - 26% 100 000 sexually active
women aged 15-49
(0) VCT + HIVNET 012 (5% coverage)
(1) VCT + HIVNET 012 (15% coverage)
(2) Family planning (contraceptive use)
CEA
[28] South Africa (UM) 18.10% 100 000 pregnant women For strategies 1 - 6, the analysis compared 1 VCT (base
case) versus 2 VCT
(1) ACTG 076 (from 28 weeks) + HIVNET 012 + ART to HIV
+ve children
(2) As (1) but without ART to HIV+ve children
(3) ACTG 076 (from 34 weeks) + HIVNET 012 + ART to HIV
+ve children
(4) As (3) but without ART to HIV+ve children
(5) HIVNET 012 + ART to HIV+ve children
(6) Same as (5) but without ART to HIV+ve children
CUA
[26] Kenya (L) 8.3% 10 000 pregnant women (0) Individual VCT
(1) Couple VCT
CEA
[38] Global, results
presented for 14
countries with
largest numbers
of HIV+ pregnant
women
1 342 199 HIV+ pregnant
women
(0) Antiretroviral therapy (WHO Option A antenatal &
intrapartum components)
(1) Strategy 0 for all HIV+ women + Family planning
CEA
[40] Tanzania (L) 6.2% 12 747 pregnancies in
catchment area in 2007 (2%
HIV prevalence)
(0) No intervention
(1) HIVNET 012
(2) HAART (WHO Option B)
CEA & CUA
[39] Malawi (L) 11% 6500 pregnant women (0) No Intervention
(1) HAART (WHO Option B)
CEA & CUA
1 According to the 2008 World Bank classification. LMIC = Low and Middle income countries. UM = Upper Middle Income $3,946 - $12,195; LM = Lower Middle
Income ($996 - $3,945); L = Low Income ($995 or less) [16].
2 Source: UNAIDS country epidemiological factsheets HIV prevalence ages 15-49 years 2009.
3 Hypothetical cohorts, except for two studies [39] and [40] based on specific patient cohorts.
4 Clinical trials and guidelines are described in Additional file 1. Where possible, we have numbered the base case (comparator) for the analysis as (0).
5 CEA = Cost Effectiveness Analysis. CUA = Cost Utility Analysis. CBA = Cost Benefit Analysis.
6 SSA = Sub-Saharan Africa.
7 ART = antiretroviral therapy.
8 VCT = voluntary counselling and testing. According to more recent terminology, all counselling and testing strategies discussed in these papers would now be
referred to as “PIHT” or provider-initiated HIV testing.
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Page 6 of 16Table 2 Economic evaluations of interventions to reduce mother to child transmission (MTCT) of HIV: study
perspective and costs
Study Perspective
1 Cost Year
&
Currency
Discount
Rate
2
Cost Breakdown
Direct costs to the public payer Indirect costs
Intervention costs
3 Costs generated or offset
4 Health system
strengthening
5
[32] SOC 1994 US$ 5% Standard
6 LMC
7 (HIV+ children) Productivity loss
due to premature
mortality (HIV+
ve
children)
PPHC 1994 US$ 5% Standard LMC (HIV+ children)
[33] PPHC US$ 5% Standard LMC (HIV+ children)
[29] PPHC 1997 US$ 3%; 6% Standard + Training Increased health
human resources
[34] PPHC US$ 3% Standard Net LMC (HIV+ children)
[30] PPHC 1998 US$ 5% Standard + Formula
feed
Net LMC (HIV+ children)
[35] PPHC 1999 US 3% Standard LMC (HIV+ children)
[37] PPHC 1997 Rand Not
stated
Standard + Training
[36] PPHC 2000 US$ Not
stated
Drugs
[23] PPHC 2001 US$ 5% Standard+ Formula
feed Elective
caesarean
LMC (HIV+ children)& HIV+
adults
8)
[25] PPHC 2000 US$ 3% Standard LMC (HIV+ children) Human resource
capacity and
infrastructure
[31] PPHC 2003 US$ 5% Standard + Formula
Feed
LMC (HIV+ children)
[27] PPHC 2003 US$ 5% Standard + Formula
Feed
LMC (HIV+ children) Treatment
costs for NVP resistance
(mothers)
[22] PPHC 2006
Indian
Rupees
5% Standard LMC (HIV+ children)
[24] PPHC 2000 US$ n/a
9 Standard + Family
planning
Program
administration costs
[28] PPHC 2003 US$ 3% Standard + Formula
Feed
LMC (HIV+ children)
[26] Not stated US$ Not
stated
Standard
[38] PPHC US$ n/a Standard
[40] Not stated 2007 US$ n/a Standard +
programme
overhead
[39] PRO 2007 US$ 3% Standard
PPHC 2007 US$ 3% Standard LMC (HIV+ children)
1SOC = Societal (considers direct and indirect costs); PPHC = Public payer of healthcare costs (considers direct costs only); PRO = Provider (considers direct
medical costs covered by the facility).
2Rates listed apply to both costs and effects.
3All studies included salary costs. Some were included as components of VCT while others constitute a separate category.
4Costs of care for HIV+ individuals averted due to the intervention or additional care required as a result of the intervention (i.e. due to adverse effects).
5Items considered by authors include start up costs such as training of personnel and investment in health system infrastructure, and ongoing costs such as the
costs of central programme administration.
6 “Standard” costs include staff time, drugs and HIV testing.
7LMC = lifetime medical costs.
8Included to quantify cost savings associated with the impact of VCT on sexual behavior change and horizontal transmission.
9n/a = non applicable.
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Page 7 of 16Table 3 Economic evaluations of interventions to reduce mother to child transmission (MTCT) of HIV: estimates of
effectiveness
1
Study Infant HIV cases averted Reduction in forward transmission
2 Life years QALYs
3 or DALYs
4
[32] (0) 3764
(1) 4250
per 100,000 births
5
n/a
6 n/a n/a
[33] (1) 0.70
(2) 0.62
(3) 0.31
per 100 women
A 30% benefit was incorporated in the base
case and varied from 10-50% in sensitivity
analyses
n/a (1) 13.2
(2) 11.6
(3) 5.8
DALYs per 100
women
[29] (1) 99
(2) 272
(3) 307
n/a n/a n/a
[34] (1) 476
(2) 603
(3) 315
(4) 229
(5) 309
per 20 000 women
A 30% benefit was considered in sensitivity
analyses.
n/a (1) 12572
(2) 15862
(3) 8326
(4) 6041
(5) 8163
DALYs per 20 000
women
[30] (Total deaths averted)
(1) 26
(2) 25
(3) 5
(4) 37
(5) 200
(6) 124
(7) 160
(8) 188
(9) 200
n/a (1) 461
(2) 449
(3) 98
(4) 661
(5) 3 655
(6) 2 260
(7) 2 926
(8) 3 434
(9) 3 654
n/a
[35] (1) 137
(2) 160
(3) 89
(4) 142
n/a n/a n/a
[36] 23 181 n/a n/a
[37] n/a n/a n/a n/a
[23] (0) 4 & 3
(1) 91 & 64
(2) 46 & 32
(3) 91 & 64
(4) 102 & 72
All reported for ACTG 076 &
HIVNET 012
30% external benefit considered in sensitivity
analyses
n/a n/a
[25] (1)
Botswana: 243
Ivory Coast: 435
Kenya: 904
Rwanda: 1 380
Tanzania: 2 774
Uganda: 1 375
Zambia: 629 Zimbabwe: 1 013
n/a n/a (1)
7
BWA: 7571
CIV: 12 984
KEN: 27 784
RWA: 39 095
TZA: 82 806
UGA: 39 846
ZMB: 18 873
ZWE: 31 462 DALYs
[31] Not given n/a (0) 446 208
(1) 445 922
(2) 447 391
(3) 451 250
(4) 446 869
(5) 446 187
QALYs
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on the delivery point of interventions to patients. Three
studies [24,25,30] considered the costs of HSS required to
provide interventions in contexts of resource scarcity.
Items considered by authors include start up costs such as
training of personnel and investment in health system
infrastructure, and the costs of programme administration.
HSS costs resemble the category of “programme costs” as
described in [42] but capture more extensive investments
in physical infrastructure and health human resources.
Indirect costs
Productivity losses due to the early death of HIV+ chil-
dren were considered by one study [33].
Choice of discount rate was quite consistent with
values of 3% or 5% most commonly used.
Effectiveness
The most common measure of effectiveness was infant
HIV infections averted, reported by 17 of 19 studies
[Table 3]. Four studies [23,34,35,39] considered the ben-
efits of MTCT interventions on horizontal transmission
by incorporating a reduction in adult-to-adult transmis-
s i o nd u et oV C T .N os t u d yc o n s i d e r e dt h ei m p a c to f
pMTCT on maternal health. More general measures of
effectiveness were also used. Two studies presented
costs per life year gained [22,31], and seven studies pre-
sented cost per QALY [29,32] or DALY [25,34,35,39,40].
Parameter values for efficacy and effectiveness were
largely drawn from clinical trials [Additional file 1]. Esti-
mated natural history rates of MTCT of HIV in the
antenatal or intrapartum period ranged from 19% to
30%. Breastfeeding transmission rates in the absence of
treatment ranged from 10% to 16%. Drug efficacy
reflected drug type and regimen, acceptance of testing
and adherence to treatment. Acceptance of HIV testing
ranged from 64% to 85% while adherence rates to anti-
retroviral therapy were estimated at around 75% for
ZDV and slightly over 90% for NVP.
Table 3 Economic evaluations of interventions to reduce mother to child transmission (MTCT) of HIV: estimates of
effectiveness
1 (Continued)
[27] (0) 233
(1) 258
(2) 273
(3) 337
(4) 245
(5) 271
(6) 300
(7) 353
n/a n/a n/a
[22] (1) 9880
(2) 4403
n/a (1) 131 700
(2) 58 700 Potential years of
life lost
n/a
[24] (1) 33.1
(2) 32.5
n/a n/a n/a
[28] (1) 3436
(2) 3436
(3) 3406
(4) 3406
(5) 5031
(6) 5031
For 2 VCT strategy
n/a n/a (1) 776.48
(2) 1158.74
(3) 1299.76
(4) 1939.63
(5) 1147.84
(6) 1712.92
QALYs for 2 VCT
strategy
[26] (1) 91
(2) 88
VCT may prevent HIV acquisition in discordant
couples where the male is HIV+ve
n/a n/a
[38] (0) 241 596
(1) 71 945 (additional)
n/a n/a n/a
[40] (1) 0.51
(2) 2.67
per 1000
n/a n/a (1) 12.9
(2) 67
per 1000
[39] (1) 370 15% benefit incorporated in base case (0%-30%
in sensitivity analyses)
n/a (1) 10 449
1Numbers in round brackets correspond to the intervention strategies presented in Table 1.
2This is reduction in adult-to-adult transmission due to VCT (voluntary counseling and testing). All studies consider provider-initiated HIV testing (PIHT)).
3QALY = Quality-adjusted life years.
4DALY = Disability-adjusted life years.
5SOC = Societal (considers direct and indirect costs); PPHC = Public payer of healthcare costs (considers direct costs only); PRO = Provider (considers direct
medical costs covered by the facility).
6n/a = not applicable.
7 These are three-letter country codes published by the International Organization for Standardization (ISO).
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Page 9 of 16Table 4 Cost-effectiveness of interventions to reduce mother to child transmission (MTCT) of HIV (2008 I$)
1, 2, 3
Study Cost per infant HIV infection
averted
Cost per life year Cost per QALY
4 or
DALY
5
Intervention C/E? (benchmark)
6
[32] (1) 3 748 (PPHC)
(1) 1 454 (SOC)
n/a n/a No
7
[33] (1) 6 515
(2) 3 401
(3) 1 433
n/a (1) 348
(2) 181
(3) 76
Cost per DALY
Yes
[29] (1) 7 368
(2) 7 095
(3) 3 162
(1) 260; 452
(2) 251; 435
(3) 112; 194
All reported as 3%; 6%
discount rate.
n/a Yes
[34] (1) 373
(2) 173
(3) 3 479
(4) 1 582
(5) 1 387
n/a (1) 14
(2) 7
(3) 132
(4) 60
(5) 52
Cost per DALY
Yes (WDR
8)
[30] (1) 4 503
(2) 5 879
(3) 25 083
(4) 7 464
(5) 3 053
(6) 315
(7) CS
9
(8) CS
(9) 837
(1) 250
(2) 323
(3) 1 390
(4) 414
(5) 167
(6) 18
(7) CS
(8) CS
(9) 46
n/a Yes (WDR)
[35] (1) 1 044
(2) 1 021
(3) 1 196
(4) 1 021
From $5-$141 n/a Yes
[36] 1 787 n/a 17 per DALY Yes
[37] n/a (1) 23
(2) 23
(3) 163
(4) 18 363
n/a Yes
[23] (0) 99 430
(1) 99 318
(2) 61 286
(3) 64 732
(4) 65 733
n/a n/a No
10
[25] BWA: 2 022
CIV: 10 354
KEN: 4 800
RWA: 2 089
TZA: 2 554
UGA: 5 432
ZMB: 2 870
ZWE: 3 996
n/a BWA: 65
CIV: 347
KEN: 157
RWA: 74
TZA: 86
UGA: 188
ZMB: 96
ZWE: 129
per DALY
Yes
[31] n/a n/a (0) 1.96
(1) 1.98
(2) 3.25
(3) 2.98
(4) 2.46
(5) 3.60
per QALY
Yes (WDR)
[27] (0) 716
(1) 851
(2) 570
(3) 556
(4) 1 740
(5) 1 776
(6) 1 381
(7) 1 266
n/a n/a Yes (Thai
12)
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Sixteen articles concluded that an MTCT intervention
was cost-effective[Table 4]. Divergent results were found
by [33], which analyzed long course AZT and reflected
older (higher) drug costs, and [22,23], which considered
very low HIV prevalence settings. Eight articles made
use of an external benchmark to justify their conclu-
sions: six [22,29,31,32,35,39] used cutoffs for cost-
effectiveness of health interventions in LMICs proposed
by the World Bank [43], two [39,40] referred to the
Commission on Macroeconomics and Health [44] while
one [28] used standards adopted by the Thai govern-
ment. The vast majority of studies included a no-inter-
vention option in their analyses; six [23,26-29,32] did
not. Many considered average rather than incremental
cost-effectiveness.
Sixteen articles performed a sensitivity analysis and all
found that results were sensitive to changes in at least
one parameter value. The most common forms of sensi-
tivity analysis used were one way, two way, scenario and
threshold. Probabilistic sensitivity analysis was used by
only five studies [25,28,29,38,40]. Cost effectiveness of
pMTCT interventions was positively correlated with
rates of HIV prevalence and highly sensitive to changes
in this variable. Drug costs, VCT costs, natural history
MTCT rate, adherence to therapy, drug efficacy, and
feeding practices also had an important effect on
implied optimal strategy.
Table 4 Cost-effectiveness of interventions to reduce mother to child transmission (MTCT) of HIV (2008 I$)
1, 2, 3
(Continued)
[22] (1) 1 824.61
(2) 709.30
(1) 136.91
(2) 64.18
n/a Yes (WDR), but relative cost-effectiveness is
questionable
10
[24] (1) 857
(2) 663
n/a n/a No
13
[28] n/a n/a (1) CS
(2) 65
(3) CS
(4) 0.5
(5) CS
(6) 12.94
Incremental costs per
QALY
Yes (WDR)
[26] n/a n/a (0) 15.34
(1) 15.39
per DALY
Yes
[38] (0) $543
(1) $359 (additional cost for family
planning)
n/a n/a Yes
[40] (1) 27 409
(2) 7 361
n/a (1) Dominated
(2) 293 per DALY
Yes/1* GDP per capita per DALY
14
[39] (1) $1010 (PRO)
(1) -$267 (PPHC)
n/a (1) $36 (PRO)
(1) -$17 (PPHC) per
DALY
Yes/$50 per DALY
8 and 1* GDP per capita per
DALY
14
1 To enhance comparability, all costs in this table are presented in 2008 International dollars (I$) using GDP deflators and purchasing power parities available
from the International Monetary Fund [54].
2 Numbers in round brackets correspond to the intervention strategies presented in Table 1. Although several studies comparing multiple strategies also provide
incremental results [27-29,40], results comparing individual strategies to a do-nothing alternative are presented where possible. The exception is [28].
3 SOC = Societal (considers direct and indirect costs); PPHC = Public payer of healthcare costs (considers direct costs only); PRO = Provider (considers direct
medical costs covered by the facility).
4 QALY = Quality-adjusted life years.
6 DALY = Disability-adjusted life years.
6 These are the study authors’ conclusions about the value of one or more interventions to prevent MTCT of HIV. If a benchmark was used to justify the
conclusion, it is provided in brackets.
7 Study based on older (higher) drug prices and lower regimen effectiveness.
8 The 1993 World Development Report: Investing in Health proposed that interventions costing less than $100 per life year saved are cost effective for middle-
income countries while $50 per life-year gained is a reasonable benchmark for low-income countries [33]. This was updated to $64 per QALY in low-income
settings ($50 per QALY gained, adjusted to 2003 dollars) by [26] and [29].
9 CS = Cost saving.
10 Concentrated epidemic; very low HIV prevalence.
11 Three-letter country codes published by the International Organization for Standardization (ISO). See Table 3.
12 Authors used the Thai health system’s thresholds for adopting health technologies as a benchmark.
13Authors’ conclusions comparing the effectiveness of an ARV-based regimen (pMTCT component 3) to a family planning strategy (pMTCT component 1). Both
strategies would likely be cost-effective using standard benchmarks.
14 The WHO Commission on Macroeconomics in Health proposed that interventions costing 1*GDP per capita per DALY should be considered “very
cost-effective”, while those costing <3*GDP per capita should be considered “cost-effective” [44].
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Study quality as assessed by the BMJ checklist was poor.
The number of methodological limitations in the 19
articles ranged from one to seven, and eleven studies
had four limitations or more[Figure 2]. Several studies
did not present the economic model adequately or did
not clearly explain how outcomes were calculated. Many
studies did not report potential conflicts of interest or
funding source; however, those that did reported fund-
ing from not-for-profit sources.
Discussion
We conducted a systematic review of the cost-effective-
ness of interventions to prevent HIV MTCT in low- and
middle-income countries. Collectively, the articles sug-
gest that interventions to prevent paediatric infections
can be cost-effective in a variety of LMIC settings as
measured against accepted international benchmarks
[16,44]. In concentrated epidemics where HIV preva-
lence in the general population is low, MTCT strategies
based on universal or targeted testing of pregnant
women may not compare well against cost-effectiveness
benchmarks, or may satisfy formal criteria for cost-
effectiveness but offer a low relative value in relation to
competing interventions to improve population health.
Study conclusions can be influenced by selection of
parameter values as well as methodological and model-
ling choices [45]. Values for epidemiological parameters
related to the natural history of MTCT and intervention
efficacy were frequently drawn from clinical trials (Addi-
tional file 1) and estimates of HIV prevalence from
UNAIDS. Sources of costing parameters were more vari-
able and potentially less accurate, particularly with
respect to the representativeness of costs estimates
drawn from specific health facilities [46]. Values for
parameter inputs were generally credible and variations
plausibly reflect real differences among studies. Results
were sensitive to changes in key input parameters such
as HIV prevalence and drug costs and advanced forms
of sensitivity analysis to investigate the impact of para-
meter uncertainty were rarely used.
Analytical methods were fairly consistent between stu-
dies. Due to the strong scientific understanding of the
natural history of HIV MTCT and the quality of the
clinical evidence surrounding mechanisms to block
transmission to infants, most studies focussed on inter-
ventions related to component 3 of the WHO strategy
(preventing HIV transmission from a woman living with
HIV to her infant) [12] and the outcome of paediatric
HIV infections prevented. HIV infections prevented
were translated by several studies into more general
measures such as life expectancy, QALYs or DALYs. No
CBA studies were found. There was considerable con-
vergence in the choice of discount rates, although a jus-
tification was rarely provided. Moreover, as costs and
health benefits were usually incurred within a very short
Figure 2 Study Quality. Limitations were assessed using a modified version of the BMJ quality assessment checklist for the conduct and
reporting of cost-effectiveness studies [16]. A higher score reflects poorer quality.
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influence results. The central policy choices surrounding
pMTCT relate to the health care payer perspective,
which was modelled by all studies. One study also con-
sidered the societal perspective; however, credible data
for judging lifetime productivity gains and losses is often
unavailable especially in developing countries. The most
i m p o r t a n ta r e ao fa n a l y t i cd i v e r g e n c ec o n c e r n e d
approaches to costing. The majority of studies consid-
ered only intervention costs and neglected costs related
to programme start up and administration, as well as
investment in health human resources and infrastruc-
ture. This is an important albeit common omission in
the cost-effectiveness literature [42] that would have
caused studies to overstate cost-effectiveness.
Modelling choices relate to the type of model and the
structure chosen for an analysis [45]. Without exception,
the 19 articles reviewed used static natural history mod-
els based on analyses of decision trees and hypothetical
Markov cohorts. Many studies did not present the mod-
elling framework in a clear and reproducible way. Mod-
elling choices and challenges likely influenced the range
of pMTCT interventions considered by analysts, as sta-
tic models depicting the natural history of HIV trans-
mission from mother to child are best suited to assess
component 3 of the recommended WHO approach.
Moreover, high-quality short-term effectiveness data
from randomised and observational studies are available
for component 3 interventions. Modelling the effects of
pMTCT components 1 and 2 may demand more com-
plex forms of model capable of capturing the dynamics
of infection and transmission in the general population,
as well as more comprehensive data permitting extrapo-
lation over longer time horizons. A dynamic modelling
approach is conceptually des i r a b l ea n dw o u l db el i k e l y
to have a significant impact on estimates of cost per
HIV infection averted, the epidemiological impact of
pMTCT, and choice of optimal prevention strategy
[24,25]. However, it would plausibly tell in the direction
of making interventions related to component 3 more
cost-effective and thus would not alter the main conclu-
sions of the review.
Limitations of this review include reliance on pub-
lished articles and English or French language sources.
Notwithstanding these limitations and variations in the
quality of analysis and reporting in this group of papers,
the general finding that short-course pMTCT interven-
tions reflecting recent (lower) drug prices can be cost-
effective in a wide variety of resource-limited contexts,
with the possible exception of low HIV prevalence
settings, emerges as a consistent message. The fact that
interventions are highly effective and confer benefits to
newborns with a long life expectancy contributes to the
robustness of results across countries and makes them
relatively insensitive to choice of outcome measure. The
high cost of case finding relative to health benefits
gained is responsible for the equivocal cost-effectiveness
result in settings of low HIV prevalence. A 2003 sys-
tematic review also found that interventions for pMTCT
using short course regimens such as CDC-Thai and
HIVNET 012 were potentially cost-effective in sub-
Saharan Africa [41].
Despite the significance of the problem and consis-
tency of the overall message, the majority of studies
model interventions of limited relevance for clinicians
and policymakers due to rapid evolution in the recom-
mended standard of care to prevent paediatric infec-
tions. Ongoing research and programme experience
have helped to define new pMTCT approaches and the
strategies reviewed have largely been superseded by
more effective and more resource-intensive clinical
options. For HIV-infected women who do not need
treatment for their own health, the WHO now proposes
two options designed to prevent MTCT while preser-
ving future treatment options for the mother [13].
(Additional file 1) In addition, WHO recommends that
appropriate antiretroviral therapy be given to HIV+
women who require it for their own health [13]. Two
studies to date have examined the currently recom-
mended approaches and confirm their cost-effectiveness
in generalised epidemic contexts [39,40]. Models high-
light the sensitivity of cost-effectiveness results to HIV
prevalence [40], suggesting challenges for efficient deliv-
ery of these interventions in very low HIV prevalence
settings.
Conclusions
The development in the early to mid 1990s of new and
very effective classes of antiretroviral drugs precipitated
a major change in the standard of care for HIV infec-
tion, initially uniquely to the benefit of residents of
wealthy countries. Early in t h ec o u r s eo ft h eH I Ve p i -
demic, representatives of major international agencies
were persuaded by the logic of cost-effectiveness that
antiretroviral treatment should be inaccessible to those
infected with HIV in developing countries [47]. In reac-
tion, many of the earlier studies reviewed were con-
cerned to demonstrate that at least one compelling use
of antiretrovirals, prevention of HIV transmission from
mother to child, could be potentially cost-effective in
even the poorest of settings. The policy dialogue
focussed on defining effective options that would be
inexpensive and feasible enough to be used in the con-
texts where need was greatest, and advocacy often
shaped methodological choices.
The dialogue has now changed in two fundamental
w a y s .F i r s t ,t h e r eh a sb e e nag e n e r a ls h i f tt o w a r d sa
more nuanced use of cost-effectiveness evidence. Rather
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ion (or as an anathema), information on efficiency is
increasingly viewed as one among a number of factors
relevant to sound policymaking [48]. Other criteria,
such as the severity of the condition and the special vul-
nerability of the primary beneficiary group, are also rele-
vant [49]. Second, the World Health Organization has
now defined guidelines for interventions to interrupt
perinatal transmission [13]. The confluence of these fac-
tors means that the central question to be addressed by
cost-effectiveness studies is no longer whether interven-
tions to prevent vertical transmission of HIV should be
offered, but rather, how best to offer the recommended
standard of care.
Future cost-effectiveness analyses can help to ensure
that pMTCT interventions for LMICs reach their full
potential by focussing on unanswered questions in four
areas.
1. Which pMTCT strategies are best in a given local
context? The set of intervention options for HIV
MTCT evolves rapidly and context-specific factors
can affect the choice of best strategy. It will continue
to be important for countries to conduct operational
research to validate the cost-effectiveness of specific
approaches in their setting, to ensure that pMTCT
strategies that reflect current clinical guidelines
[13,14] and are technically efficient are privileged.
The cost-effectiveness of several important options
remains to be evaluated in LMICs, among them:
(i) new diagnostic technologies such as combined
point of care diagnostic tests for HIV and other
STDs; (ii) innovative strategies for reaching under-
served populations (particularly in rural areas) such
as the Mother-Baby Pack developed by UNICEF and
partners to increase the uptake of more efficacious
ARV prophylactic regimens for PMTCT in resource-
limited settings, in line with the most recent WHO
guidelines [13]; (iii) post-exposure prophylaxis for
infants born to women who have not received an
ante partum drug regimen; (iv) alternative laboratory
strategies such as use of PCR for infant HIV testing.
New diagnostic and laboratory options have the
potential to figure as important cost drivers.
2. How can coverage of MTCT interventions in
LMICs be improved? Despite the remarkable scienti-
fic advances of the last 15 years, pMTCT program
coverage remains low in most LMICs [12]. A crucial
question is hence how best to scale up programmes
to reach underserved populations. This issue is parti-
cularly challenging where facility-based antenatal
care attendance is low, a problem disproportionately
affecting residents of rural areas. None of the studies
reviewed considered the impact of programme scale
on the cost-effectiveness ratio. The following ques-
tions are central: in which types of epidemic condi-
tions is it important to reach underserved
populations? Which mechanisms are most effective?
What level of infrastructure is required to imple-
ment the interventions, or to scale up the interven-
tions? [50] If strategies to reach rural, remote and
underserved urban populations are not cost-effective
or are less cost-effective than those for other groups,
are there ethical or pragmatic reasons that they
should nonetheless be implemented?
3 .C a nw ee v a l u a t eam o r ec o m p r e h e n s i v es e to f
pMTCT options? Current models have focussed
overwhelmingly on component 3 (perinatal transmis-
sion) of the recommended WHO pMTCT approach.
To evaluate how funds for pMTCT should best be
spent would properly require a broader framework
in which the value of all 4 pillars of the strategy can
be considered [12,24,25]. Since models are generally
based on incremental analysis, failure to include
appropriate strategies can lead to erroneous policy
conclusions. Development of a comprehensive per-
spective poses new challenges that may require
going beyond a static modelling approach. In addi-
tion to focussing on the natural history of mother-
to-child transmission and interventions to block
infant infection, the ideal model would also assess
HIV transmission dynamics among adults to capture
the value of primary prevention strategies and be
capable of considering the value of early and appro-
priate care for adult HIV+ women and their infants.
4. How should pMTCT services best be organised
and delivered to strengthen health systems and
improve the health of women and children? While
existing MTCT services are often offered vertically,
fostering linkages to maternal, newborn and child
health programmes and sexual and reproductive
health programmes offers an opportunity to improve
programme efficiency and equity, to further attain-
ment of the goals set by the UN General Assembly
for HIV [51], and to help fulfil the health related Mil-
lennium Development Goals (MDGs) [12]. Although
examples of service integration models are beginning
to emerge [52] many questions remain. What are the
benefits and costs of linked services, including costs
and cost-effectiveness? Which models work best in
which contexts? [12,53] Answers are urgently needed.
Though cost-effectiveness considerations should con-
tribute to the design of integrated services, these
questions challenge mainstream cost-effectiveness
methods as they require cost-effectiveness models to
assess a broad range of interventions in a comparable
way and to consider the potential benefits of pro-
gramme synergies [48].
Johri and Ako-Arrey Cost Effectiveness and Resource Allocation 2011, 9:3
http://www.resource-allocation.com/content/9/1/3
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are likely to depend on features of the local context
such as HIV epidemic type, the epidemiology of HIV
and other conditions affecting the health of women and
children, country resource levels, pricing of drugs and
technologies, and local values. By addressing them,
operational research on cost-effectiveness can play an
important role in helping to realise the full potential of
pMTCT interventions to prevent paediatric infections
and promote the health of mother and child.
Additional material
Additional file 1: Appendix 1. Clinical trials and guidelines used to
inform intervention strategies for the economic evaluations
included in this review. Overview of clinical trials and guidelines used
to inform cost-effectiveness studies included in the review
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